iCAD To Showcase Five AI-Powered Research Presentations Advancing Breast Cancer Detection, Risk Evaluation, and Breast Arterial Calcification Assessment at ECR 2025

Core Insights - iCAD, Inc. is a global leader in AI-powered breast health solutions, focusing on advancements in breast cancer detection and risk evaluation, with five clinical presentations accepted at ECR 2025 [1][2][3] Group 1: Company Developments - iCAD will present the new ProFound Cloud, a secure and scalable SaaS platform designed to deliver advanced AI solutions to healthcare providers globally [3] - The company emphasizes its commitment to AI innovation in breast health, showcasing how its solutions improve personalized risk evaluation and early detection [3][5] Group 2: Clinical Presentations - Five clinical presentations will cover topics such as a 10-year image-derived AI risk model for breast cancer prevention and the optimal use of AI diagnostic software in mammography screening [6] - iCAD will showcase its latest innovations, including the ProFound Cloud, which offers access to a full suite of solutions like DBT Detection and Risk Assessment [5][6] Group 3: Industry Impact - The studies presented at ECR 2025 highlight the real-world impact of iCAD's solutions on clinical outcomes and workflow efficiency for radiologists [2][3] - iCAD's ProFound Breast Health Suite is used by thousands of providers in over 50 countries, having read more than 40 million mammograms in the last five years [8]